Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Status: AVAILABLE
Study type: EXPANDED_ACCESS
Conditions: Non Small Cell Lung Cancer|Medullary Thyroid Cancer|Colon Cancer|Breast Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Other Solid Tumors With Evidence of Activating RET Alteration
Interventions: DRUG: Selpercatinib
Sponsor: Loxo Oncology, Inc.
Collaborators: Eli Lilly and Company